BSEGeneral2h ago · 3 Oct 2026, 05:41 pm
Allotment of 1,82,400 Equity Shares to Non-Promoter Allottees pursuant to conversion of 60,800 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.
Fredun Pharmaceuticals Ltd · 539730
✦ AI SummaryBonus/Split
Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares to non-promoter allottees pursuant to the conversion of 60,800 warrants into equity shares, consequent to the 1:2 bonus issue.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Allotment Of 1,82,400 Equity Shares To Non-Promoter Allottees Pursuant To Conversion Of 60,800 Warrants Into Equity Shares, Consequent To The 1:2 Bonus Issue.
Attachments (1)
📄pdf
Download →
62b91c7b-2b5e-4306-978e-1fe5777a7cba.pdf
View document text
Date: 03rd October, 2026
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.
Ref.: BSE Scrip Code - 539730
Subject: Outcome of Board Meeting Dated 03rd October, 2026
Re: Allotment of 1,82,400 Equity Shares to Non-Promoter Allottees pursuant to conversion of 60,800
Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.
Dear Sir,
This is to inform you that Board of Directors of the Company had pursuant to the approval of
Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible
warrants on preferential basis to Allottees on December 29, 2025 allotted convertible warrants on a
preferential basis to the respective allottees.
Further, we would like to inform you that the Warrant Holders have paid the balance of the consideration
and have applied for exercising their rights for conversion of 60,800 warrants into 1,82,400 number of
Equity Shares.
Consequently, the Board of Directors in its meeting held on October 03, 2026 has allotted 1,82,400 Equity
Shares of face value Rs. 10/- each to the warrant holder as per following details:
Sr. Name of Allottee Category Total Number of Number of After
No. of Investor number of Equity Shares Warrants effect of
convertible allotted upon Outstanding Bonus
warrants conversion of for issue in
allotted on Warrants on Conversion Ratio
December October 03, 1:2
29, 2025 2026#
1 Rashmi Jain Non- 4,000 4,000 0 12,000
Promoter
2 Swati Goel Non- 8,000 2,667 0 8,000
Promoter
3 Divya Aggarwal Non- 8,000 2,133 2,667 6,400
Promoter
4 Reshma M Kukreja Non- 800 800 0 2,400
Promoter
5 Girdhari T Non- 16,000 16,000 0 48,000
Jaisinghani Promoter
6 Nikhil R Non- 16,000 16,000 0 48,000
Jaisinghani Promoter
7 R. R. Family Trust Non- 13,600 13,600 0 40,800
Promoter
8 Vivek Dhir Non- 800 800 0 2,400
Promoter
9 Ceramet Non- 800 800 0 2,400
Consultants Promoter
Private Limited
10 Nav Ratan Bhaiya Non- 4,000 4,000 0 12,000
Promoter
TOTAL 72,000 60,800 2,667 1,82,400
#After the Company’s 1:2 Bonus Issue, the entitlement on outstanding warrants is proportionately
adjusted, giving each warrant the right to the increased number of equity shares with the exercise price
revised accordingly.
The allotment of the equity shares shall be made in dematerialized form and the equity shares so allotted
shall rank pari passu with the existing Equity Shares of the Company in all respects.
The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 read with the SEBI Master Circular dated January 30, 2026 are enclosed
as “Annexure I”.
The meeting commenced at 04:00 p.m. and concluded at 05:15 p.m.
Kindly take the aforesaid information on your records.
Thanking you,
FOR FREDUN PHARMACEUTICALS LIMITED
FREDUN NARIMAN MEDHORA
MANAGING DIRECTOR
DIN NO.: 01745348
Encl. : Annexure I
Annexure I
Information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015
Issuance of Securities:
Sr. Particulars of Securities Details of Securities
a) Type of securities proposed to be Equity Shares upon conversion of Warrants into Equity
issued Shares of Rs. 10/- each.
b) Type of issuance Preferential Issue in accordance with Chapter V of the
SEBI ICDR Regulations 2018 and other applicable law.
c) Total number of securities Allotment of 1,82,400
proposed to be issued or the total
amount for which the securities Fully Paid-Up Equity Shares.
will be issued
In case of preferential issue, the listed entity shall disclose the following additional details to the
stock exchange(s):
i. Name of Investors Mentioned in the Covering Letter above.
ii. Post Allotment of securities - Warrants were allotted on December 29, 2025, carrying
outcome of the subscription, the right to subscribe to Equity Shares upon exercise of
issue price / allotted price (in the option attached to each warrant, at an issue price of
case of convertibles), Rs. 1,250/- per warrant, of which Rs. 312.50/- per
warrant, being 25% of the issue price, was payable
upfront. Subsequently, pursuant to the 1:2 Bonus Issue
made by the Company, the entitlement attached to the
outstanding warrants was adjusted in accordance with
the applicable provisions of the SEBI (Issue of Capital and
Disclosure Requirements) Regulations, 2018.
Accordingly, pursuant to such adjustment, 60,800
outstanding warrants were exercisable into 1,82,400
Equity Shares, i.e. three Equity Shares for each
outstanding warrant, upon payment of the applicable
balance consideration..
iii. No. of Investors 10 (Ten)
iv. In case of convertibles - As the total consideration of the 60,800 Convertible
intimation on conversion of Warrants is received, the Equity Shares are allotted
securities or on lapse of the pursuant to exercise of the conversion of Convertible
tenure of the instrument; Warrants.
v. Any cancellation or termination Not Applicable
of proposal for issuance of
securities including reasons
thereof.